肺功能与皮肤纤维化变化可预测系统性硬化症相关间质性肺病生存:一项EUSTAR研究
基于EUSTAR数据库893例成人SSc-ILD患者,评估12个月内肺功能、mRSS及指端溃疡负荷变化与生存的关联。平均随访39.0±23.9个月期间94例(10.5%)死亡。12个月内FVC绝对下降>10%pred可预测生存降低(HR 3.81;95%CI 1.67-8.66),复合指标亦有预测价值。
要点
- 12个月内FVC下降>10%pred与生存降低相关(HR 3.81;95%CI 1.67-8.66)。
- FVC下降>10%或mRSS恶化复合指标与生存降低相关(HR 2.82;95%CI 1.43-5.56)。
- FVC下降≥10%或5-9%伴DLCO下降≥15%复合指标与生存降低相关(HR 3.42;95%CI 1.68-7.00)。
核心结论
- 作者认为评估死亡风险时应考虑12个月内肺功能和皮肤纤维化的变化。
- 作者建议应在临床试验中前瞻性评估旨在稳定这些变量的药物治疗效果。
研究设计与样本
- 研究纳入自2009年1月起入组EUSTAR数据库的成人SSc-ILD患者,需有诊断日期、12个月内用于变化评估的随访访视及进一步访视或死亡信息。
- 采用多变量Cox回归分析评估12个月内肺功能(FVC%pred和DLCO%pred)、mRSS及指端溃疡负荷变化与生存的关联,校正年龄、性别、吸烟状态和免疫抑制治疗。
主要发现
- 共纳入893例SSc-ILD患者,平均随访39.0±23.9个月期间94例(10.5%)死亡。
- 12个月内FVC绝对下降>10%pred(可评估者中78/638例)可预测生存降低(HR 3.81;95%CI 1.67-8.66)。
- FVC下降>10%或mRSS恶化的复合指标与生存降低相关(HR 2.82;95%CI 1.43-5.56)。
- FVC下降≥10%或5-9%伴DLCO下降≥15%的复合指标与生存降低相关(HR 3.42;95%CI 1.68-7.00)。
- DLCO、mRSS或指端溃疡负荷单独变化与生存无显著关联。
关键数值与推荐
- FVC绝对下降>10%pred(12个月内)预测生存降低:HR 3.81;95%CI 1.67-8.66。
- FVC下降>10%或mRSS恶化复合指标:HR 2.82;95%CI 1.43-5.56。
- FVC下降≥10%或5-9%伴DLCO下降≥15%复合指标:HR 3.42;95%CI 1.68-7.00。
临床怎么用
- 作者认为评估死亡风险时应考虑12个月内肺功能和皮肤纤维化的变化。
- 作者建议应在临床试验中前瞻性评估旨在稳定这些变量的药物治疗效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study assessed how changes in lung function, skin fibrosis and digital ulceration (DU) burden predict mortality in patients with SSc-associated interstitial lung disease (SSc-ILD), the leading cause of death in SSc. METHODS: Adult SSc-ILD patients from the European Scleroderma Trials and Research (EUSTAR) database enrolled since January 2009 with a date of diagnosis, a follow-up visit for change evaluation within 12 months plus a further visit or mortality information were eligible. Twelve-month changes in lung function (per cent predicted forced vital capacity [FVC%pred] and diffusing capacity of the lungs for carbon monoxide [DLCO%pred]), modified Rodnan skin score (mRSS) and change in DU burden were assessed for associations with survival, using multivariable Cox regression analyses adjusted for age, sex, smoking status and immunosuppressive therapy. RESULTS: Of 893 SSc-ILD patients included, 94 (10.5%) died over a mean follow-up of 39.0 ± 23.9 months. Absolute deterioration in FVC >10%pred within 12 months (n = 78/638 evaluable) was predictive for decreased survival (hazard ratio [HR] 3.81; 95% CI 1.67-8.66), as were composite measures combining (i) >10% FVC decline or mRSS worsening (HR 2.82; 95% CI 1.43-5.56) and (ii) FVC decline ≥10% or 5-9% with DLCO decline ≥15% (HR 3.42; 95% CI 1.68-7.00), but not changes in DLCO, mRSS or DU burden alone. CONCLUSIONS: Changes in lung function and skin fibrosis within 12 months should be considered when evaluating risk of mortality. The effect of pharmacological treatments aiming at stabilization of these variables should be evaluated prospectively in clinical trials.
引用
- Sobanski V, de Vries-Bouwstra J, Hoffmann-Vold AM, et al. Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR study. Rheumatology (Oxford). 2025. PMID: 40457805. doi:10.1093/rheumatology/keaf264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。